Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...15041505150615071508150915101511151215131514...15771578»
  • ||||||||||  Trial completion, Trial primary completion date:  MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study (clinicaltrials.gov) -  Apr 26, 2017   
    P=N/A,  N=15, Completed, 
    Recruiting --> Active, not recruiting | N=120 --> 64 | Trial primary completion date: Mar 2017 --> Mar 2022 Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jan 2017
  • ||||||||||  Journal:  Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model. (Pubmed Central) -  Apr 26, 2017   
    However, the transformed MSC cells and standard osteosarcoma cell lines maintained their tri-lineage differentiation capacity. The inability of the transformed pOB cell line to undergo adipogenic differentiation, may suggest that osteosarcoma is derived from a cell intermediate in differentiation between an MSC and a pOB, with partial commitment to the osteoblastic lineage.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment closed, Enrollment change, Trial primary completion date:  Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) (clinicaltrials.gov) -  Apr 25, 2017   
    P2/3,  N=233, Active, not recruiting, 
    In summary, we report a subset of cellular variants of myofibroma and myopericytoma showing a smooth muscle-like immunophenotype and harboring recurrent SRF-RELA gene fusions, which mimic sarcomas with myogenic differentiation. Recruiting --> Active, not recruiting | N=318 --> 233 | Trial primary completion date: Dec 2017 --> Apr 2017
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Zaltrap (ziv-aflibercept IV) / Sanofi
    Trial primary completion date, PD(L)-1 Biomarker, Metastases:  Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov) -  Apr 24, 2017   
    P1,  N=36, Recruiting, 
    Trial primary completion date: Dec 2018 --> Dec 2028 Trial primary completion date: Apr 2017 --> Dec 2018
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Trial primary completion date, Metastases:  TVEC and Preop Radiation for Sarcoma (4 ml Dose) (clinicaltrials.gov) -  Apr 24, 2017   
    P1/2,  N=32, Recruiting, 
    Suspended --> Recruiting Trial primary completion date: Apr 2017 --> Apr 2018
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment change, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases:  Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (clinicaltrials.gov) -  Apr 21, 2017   
    P2,  N=37, Suspended, 
    We show that mutations in RNase L found in HPC patients may promote prostate cancer by increasing expression of AR-responsive genes and cell motility and identify novel roles of RNase L as a prostate cancer susceptibility gene. N=12 --> 37 | Trial primary completion date: Jul 2016 --> Jan 2018
  • ||||||||||  Journal:  Primitive Neuroectodermal Tumor of the Stomach: A Case Report. (Pubmed Central) -  Apr 20, 2017   
    ES/PNET is frequently misdiagnosed because of its similarity with small cell carcinoma. Although gastric ES/PNET is very rare, it should be included in differential diagnoses of small round cell tumor in the stomach.
  • ||||||||||  Journal:  Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma. (Pubmed Central) -  Apr 20, 2017   
    After expert consultation and additional immunohistochemical stains for muscle markers, a diagnosis was rendered of primary rhabdomyosarcoma arising in association with a pituitary adenoma. Despite its rarity, a high index of suspicion for rhabdomyosarcoma arising within a pituitary adenoma should be maintained in cases of atypical pituitary adenoma with a stromal response.
  • ||||||||||  Trial completion:  Ensuring Communication in Hospice by Oncology Study (ECHO) (clinicaltrials.gov) -  Apr 18, 2017   
    P=N/A,  N=30, Completed, 
    Phase classification: P=N/A --> P | Trial primary completion date: Jul 2017 --> Jul 2018 Active, not recruiting --> Completed
  • ||||||||||  Biomarker, Phase classification, Trial primary completion date:  3T MRI Biomarkers of Glioma Treatment Response (clinicaltrials.gov) -  Apr 17, 2017   
    P,  N=7, Terminated, 
    Active, not recruiting --> Recruiting | N=62 --> 9 Phase classification: P=N/A --> P | Trial primary completion date: Nov 2017 --> Nov 2015
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment open:  Optune (clinicaltrials.gov) -  Apr 16, 2017   
    P2,  N=85, Recruiting, 
    Phase classification: P=N/A --> P | Trial primary completion date: Nov 2017 --> Nov 2015 Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Targeted therapy for soft tissue sarcomas in adolescents and young adults. (Pubmed Central) -  Apr 16, 2017   
    Over the last two decades, our understanding of the biology of STSs is slowly increasing, allowing for the development of more targeted therapies. We review the new treatment modalities that have been tested on patients with STSs, with a special focus on adolescents and young adults, a group of patients that is often underrepresented in clinical trials and has not received the dedicated attention it deserves, given the significant differences in biology and treatment response in comparison to children and adults.